Revista Espanola De Medicina Nuclear E Imagen Molecular最新文献_第6页

Resultados e incidencia de hipotiroidismo tras el tratamiento del hipertiroidismo con yodo radiactivo a dosis bajas 用低剂量放射性碘治疗甲状腺机能亢进后甲状腺功能减退的结果和发病率

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-03-01 DOI: 10.1016/j.remn.2024.500056

K.-H. Lin , J.-C. Wu , M.-C. Wu

Objective

The study aimed to analyze the outcome of low-dose radioactive iodine (RAI) treatment for hyperthyroidism, disclose whether age and gender influence the outcome, and determine the incidence and onset time of hypothyroidism following low-dose RAI.

Material and methods

A total of 158 patients who received doses less than 370 Mbq RAI were enrolled in the study. Treatment outcome and incidence of hypothyroidism were compared between different gender (45 male vs. 113 female), age (77 patients ≥ 45 years old vs. 81 patients < 45 years old) and dose (39 patients receiving higher doses RAI vs. 119 receiving lower dose with a cutoff of 222 MBq) groups. Treatment outcomes were categorized into post-treatment hypothyroidism, treatment failure (persistent hyperthyroidism), and euthyroidism. In those becoming hypothyroid, time to develop hypothyroidism was calculated for cumulative incidences over time.

Results

Out of 158 patients, 47 (29.7%) developed hypothyroidism, 101 (63.9%) had treatment failure, and 10 (6.3%) remained euthyroid after treatment. Response rates (33.6% vs. 43.5%, P = .260) and hypothyroidism incidences (26.9% vs. 38.5%, P = .170) did not differ significantly between lower and higher dose groups, neither between lower and higher age groups (P = .69 in response rates and P = .75 in hypothyroidism incidence). Females exhibited higher response rates (42.5% vs. 20.0%, P = .008) and hypothyroidism incidence (46.3% vs. 13.3%, P = .004) compared to males. Hypothyroidism onset occurred at a mean of 24.0 ± 29.2 months, and the cumulative incidences over time were 47% and 60% in six and twelve months, respectively.

Conclusions

Low-dose RAI has a low response rate for treating hyperthyroidism. Although there may be a lower incidence of hypothyroidism following low-dose RAI compared to high-dose RAI, hypothyroidism may occur early after treatment. Besides, females have higher response rates but more incidence of hypothyroidism. The balance between the risks and benefits of using low-dose RAI should be taken into deliberate consideration.

目的分析低剂量放射性碘（RAI）治疗甲状腺功能亢进的疗效，揭示年龄和性别是否影响疗效，确定低剂量放射性碘治疗后甲状腺功能减退的发生率和发病时间。材料和方法共有158名接受低于370 Mbq RAI剂量的患者入组研究。比较不同性别（男性45例，女性113例）、年龄(≥45岁77例，女性81例；45岁)和剂量组（39例患者接受高剂量RAI， 119例患者接受低剂量RAI，截止时间为222 MBq）。治疗结果分为治疗后甲状腺功能减退、治疗失败（持续性甲状腺功能亢进）和甲状腺功能亢进。在甲状腺功能减退的患者中，甲状腺功能减退的发病时间是根据累积发病率计算的。结果158例患者中，47例（29.7%）出现甲状腺功能减退，101例（63.9%）治疗失败，10例（6.3%）治疗后甲状腺功能正常。反应率（33.6%对43.5%,P = 0.260）和甲状腺功能减退发生率（26.9%对38.5%,P = 0.170）在低剂量组和高剂量组之间无显著差异（反应率P = 0.69，甲状腺功能减退发生率P = 0.75）。女性的有效率（42.5% vs. 20.0%, P = 0.008）和甲状腺功能减退发生率（46.3% vs. 13.3%, P = 0.004）均高于男性。甲状腺功能减退的发病时间平均为24.0±29.2个月，6个月和12个月的累计发病率分别为47%和60%。结论慢剂量RAI治疗甲亢有效率低。虽然与高剂量RAI相比，低剂量RAI后甲状腺功能减退的发生率可能较低，但甲状腺功能减退可能在治疗后早期发生。此外，女性应答率较高，但甲状腺功能减退的发生率较高。应慎重考虑使用低剂量RAI的风险和收益之间的平衡。

{"title":"Resultados e incidencia de hipotiroidismo tras el tratamiento del hipertiroidismo con yodo radiactivo a dosis bajas","authors":"K.-H. Lin , J.-C. Wu , M.-C. Wu","doi":"10.1016/j.remn.2024.500056","DOIUrl":"10.1016/j.remn.2024.500056","url":null,"abstract":"<div><h3>Objective</h3><div>The study aimed to analyze the outcome of low-dose radioactive iodine (RAI) treatment for hyperthyroidism, disclose whether age and gender influence the outcome, and determine the incidence and onset time of hypothyroidism following low-dose RAI.</div></div><div><h3>Material and methods</h3><div>A total of 158 patients who received doses less than 370Mbq RAI were enrolled in the study. Treatment outcome and incidence of hypothyroidism were compared between different gender (45 male vs. 113 female), age (77 patients ≥45years old vs. 81 patients <45years old) and dose (39 patients receiving higher doses RAI vs. 119 receiving lower dose with a cutoff of 222MBq) groups. Treatment outcomes were categorized into post-treatment hypothyroidism, treatment failure (persistent hyperthyroidism), and euthyroidism. In those becoming hypothyroid, time to develop hypothyroidism was calculated for cumulative incidences over time.</div></div><div><h3>Results</h3><div>Out of 158 patients, 47 (29.7%) developed hypothyroidism, 101 (63.9%) had treatment failure, and 10 (6.3%) remained euthyroid after treatment. Response rates (33.6% vs. 43.5%, <em>P</em>  =.170) did not differ significantly between lower and higher dose groups, neither between lower and higher age groups (<em>P</em>  =.75 in hypothyroidism incidence). Females exhibited higher response rates (42.5% vs. 20.0%, <em>P</em>  =.004) compared to males. Hypothyroidism onset occurred at a mean of 24.0±29.2 months, and the cumulative incidences over time were 47% and 60% in six and twelve months, respectively.</div></div><div><h3>Conclusions</h3><div>Low-dose RAI has a low response rate for treating hyperthyroidism. Although there may be a lower incidence of hypothyroidism following low-dose RAI compared to high-dose RAI, hypothyroidism may occur early after treatment. Besides, females have higher response rates but more incidence of hypothyroidism. The balance between the risks and benefits of using low-dose RAI should be taken into deliberate consideration.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500056"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Valor de la PET/TC con [18F]FDG en el diagnóstico y grado histopatológico de los adenomas colorrectales incidentales 带[18F]FDG的PET/TC在结肠直肠腺瘤的诊断和组织病理学程度方面的价值

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-03-01 DOI: 10.1016/j.remn.2024.500075

Z. Qi , K. Tang , X. Lu , Y. Zhu , N. Xu

Purpose

Colorectal adenomas (CRAs) are at a higher risk of progressing to colorectal cancer (CRC) as their histological grade increases. Herein, this study investigated the relationship between the maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography-computed tomography ([¹⁸F]FDG PET/CT) and the histological grades of CRAs and constructed the optimal regression model for distinguishing between different histological grades.

Methods

This study retrospectively analyzed the data of 153 patients with CRAs who had colorectal [¹⁸F]FDG uptake incidentally found on PET/CT. The patients were categorized into low-grade intraepithelial neoplasia (LGIN) and high-grade intraepithelial neoplasia (HGIN) groups based on their histological grade. After the analysis of the relationship between SUVmax measured on preoperative [¹⁸F]FDG PET/CT scans and histological grades, receiver-operating characteristic (ROC) curves were analyzed to determine the optimal cut-off values for distinguishing between the two groups. Common clinical and pathological factors were included and subjected to univariate and multivariate logistic regression analyses to identify independent risk factors. A diagnostic model integrating SUVmax and several risk factors was developed with the multivariate logistic regression analysis.

Results

SUVmax was significantly different between the two groups (P < .001) and increased with an elevation in the malignancy degree. The area under the ROC curve (AUC) for identifying LGIN and HGIN was 0.796, and the AUC of the combination model was 0.822. Furthermore, SUVmax was an independent risk factor for distinguishing between different histological grades in pairwise comparisons.

Conclusion

The regression model involving SUVmax on [¹⁸F]FDG PET/CT can distinguish between histological grades of CRAs, which therefore can be used as a noninvasive tool for the accurate diagnosis of CRAs and assist in developing patient-specific treatment strategies before surgery.

目的：结直肠腺瘤（CRAs）随着其组织学分级的增加，其发展为结直肠癌（CRC）的风险更高。本研究探讨了18F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描（[18F]FDG PET/CT）的最大标准化摄取值（SUVmax）与cra组织分级的关系，并构建了区分不同组织分级的最优回归模型。方法回顾性分析153例经PET/CT偶然发现结直肠FDG摄取的cra患者的资料[18F]。根据组织学分级将患者分为低级别上皮内瘤变（LGIN）组和高级别上皮内瘤变（HGIN）组。在分析术前[18F]FDG PET/CT扫描测量的SUVmax与组织学分级的关系后，分析受试者工作特征（ROC）曲线，以确定区分两组的最佳截止值。纳入常见的临床和病理因素，并进行单因素和多因素logistic回归分析，以确定独立的危险因素。通过多因素logistic回归分析，建立了SUVmax与多个危险因素的综合诊断模型。结果两组间suvmax差异有统计学意义(P <；.001)，并随恶性程度的升高而升高。识别LGIN和HGIN的ROC曲线下面积（AUC）为0.796，联合模型的AUC为0.822。此外，在两两比较中，SUVmax是区分不同组织学分级的独立危险因素。结论[18F]FDG PET/CT上涉及SUVmax的回归模型可区分cra的组织学分级，可作为准确诊断cra的无创工具，有助于术前制定患者特异性治疗策略。

{"title":"Valor de la PET/TC con [18F]FDG en el diagnóstico y grado histopatológico de los adenomas colorrectales incidentales","authors":"Z. Qi , K. Tang , X. Lu , Y. Zhu , N. Xu","doi":"10.1016/j.remn.2024.500075","DOIUrl":"10.1016/j.remn.2024.500075","url":null,"abstract":"<div><h3>Purpose</h3><div>Colorectal adenomas (CRAs) are at a higher risk of progressing to colorectal cancer (CRC) as their histological grade increases. Herein, this study investigated the relationship between the maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography-computed tomography ([<sup>18</sup>F]FDG PET/CT) and the histological grades of CRAs and constructed the optimal regression model for distinguishing between different histological grades.</div></div><div><h3>Methods</h3><div>This study retrospectively analyzed the data of 153 patients with CRAs who had colorectal [<sup>18</sup>F]FDG uptake incidentally found on PET/CT. The patients were categorized into low-grade intraepithelial neoplasia (LGIN) and high-grade intraepithelial neoplasia (HGIN) groups based on their histological grade. After the analysis of the relationship between SUVmax measured on preoperative [<sup>18</sup>F]FDG PET/CT scans and histological grades, receiver-operating characteristic (ROC) curves were analyzed to determine the optimal cut-off values for distinguishing between the two groups. Common clinical and pathological factors were included and subjected to univariate and multivariate logistic regression analyses to identify independent risk factors. A diagnostic model integrating SUVmax and several risk factors was developed with the multivariate logistic regression analysis.</div></div><div><h3>Results</h3><div>SUVmax was significantly different between the two groups (<em>P</em>  <!-->.001) and increased with an elevation in the malignancy degree. The area under the ROC curve (AUC) for identifying LGIN and HGIN was 0.796, and the AUC of the combination model was 0.822. Furthermore, SUVmax was an independent risk factor for distinguishing between different histological grades in pairwise comparisons.</div></div><div><h3>Conclusion</h3><div>The regression model involving SUVmax on [<sup>18</sup>F]FDG PET/CT can distinguish between histological grades of CRAs, which therefore can be used as a noninvasive tool for the accurate diagnosis of CRAs and assist in developing patient-specific treatment strategies before surgery.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500075"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparación de la estadificación mediante [68Ga]Ga-PSMA-11 PET/TC y los resultados anatomopatológicos en pacientes con cáncer de próstata de riesgo intermedio y alto tratados con prostatectomía radical y linfadenectomía pélvica 采用[68Ga]Ga-PSMA-11 PET/TC测定与根治性前列腺切除术和盆腔淋巴结切除术治疗的中、高风险前列腺癌患者的解剖病理学结果的比较

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-03-01 DOI: 10.1016/j.remn.2024.500076

J.J. Rosales , V. Betech Antar , F. Mínguez , F. Pareja , F. Guillén , E. Prieto , G. Quincoces , F. Díez Caballero , B. Miñana , J.L. Pérez-Gracia , M. Rodríguez-Fraile

Objective

To evaluate the diagnostic accuracy of [⁶⁸Ga]Ga-PSMA-11 PET/CT (PET-PSMA) in local and loco-regional nodal staging compared with histopathological results in intermediate- and high-risk prostate cancer patients treated with radical prostatectomy (RP) and pelvic lymph node dissection (PLND).

Materials y methods

A total of 122 intermediate- and high-risk prostate cancer (PCa) patients staged with PET-PSMA and treated with RP (36/122) and RP plus PLND (86/122) from December 2018 to December 2023 were included. Visual and semiquantitative analysis findings using the SUVmax of the molecular imaging were correlated with histopathological results.

Results

The primary tumor was visible by PET-PSMA in 96.7% of the patients. A positive correlation was found between PSA levels and SUVmax (Spearman's r: 0.303, p< 0.001). PET-PSMA detected nodal involvement in 25/89 patients (28.08%). The sensitivity, specificity, and diagnostic accuracy of PET-PSMA for detecting nodal involvement were 75%, 82.2%, and 80.9%, respectively. Patients with PSA levels >20 ng/ml, Gleason score ≥7b, ISUP grade >2, and extracapsular extension showed significantly higher SUVmax values. No differences were observed in SUVmax between risk groups or in other histopathological variables.

Conclusions

PET-PSMA is an effective tool for the initial staging of intermediate- and high-risk PCa. SUVmax values were significantly higher in patients with unfavorable clinical features.

目的评价[68Ga]Ga-PSMA-11 PET/CT （PET- psma）对中高危前列腺癌根治性前列腺切除术（RP）联合盆腔淋巴结清扫术（PLND）局部及局部区域淋巴结分期的诊断准确性，并与病理结果进行比较。方法2018年12月至2023年12月共纳入122例PET-PSMA分期并接受RP（36/122）和RP + PLND（86/122）治疗的中高危前列腺癌（PCa）患者。使用分子成像的SUVmax进行视觉和半定量分析的结果与组织病理学结果相关。结果96.7%的患者PET-PSMA显示原发肿瘤。PSA水平与SUVmax呈正相关(Spearman’s r: 0.303, p<；0.001)。89例患者中有25例（28.08%）PET-PSMA检测到淋巴结受累。PET-PSMA检测淋巴结受累的敏感性、特异性和诊断准确性分别为75%、82.2%和80.9%。PSA水平为20 ng/ml、Gleason评分≥7b、ISUP分级为2级、囊外延伸的患者SUVmax值明显升高。危险组间SUVmax或其他组织病理学变量均无差异。结论pet - psma是中高危前列腺癌早期分期的有效工具。具有不良临床特征的患者的SUVmax值明显更高。

{"title":"Comparación de la estadificación mediante [68Ga]Ga-PSMA-11 PET/TC y los resultados anatomopatológicos en pacientes con cáncer de próstata de riesgo intermedio y alto tratados con prostatectomía radical y linfadenectomía pélvica","authors":"J.J. Rosales , V. Betech Antar , F. Mínguez , F. Pareja , F. Guillén , E. Prieto , G. Quincoces , F. Díez Caballero , B. Miñana , J.L. Pérez-Gracia , M. Rodríguez-Fraile","doi":"10.1016/j.remn.2024.500076","DOIUrl":"10.1016/j.remn.2024.500076","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the diagnostic accuracy of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT (PET-PSMA) in local and loco-regional nodal staging compared with histopathological results in intermediate- and high-risk prostate cancer patients treated with radical prostatectomy (RP) and pelvic lymph node dissection (PLND).</div></div><div><h3>Materials y methods</h3><div>A total of 122 intermediate- and high-risk prostate cancer (PCa) patients staged with PET-PSMA and treated with RP (36/122) and RP plus PLND (86/122) from December 2018 to December 2023 were included. Visual and semiquantitative analysis findings using the SUVmax of the molecular imaging were correlated with histopathological results.</div></div><div><h3>Results</h3><div>The primary tumor was visible by PET-PSMA in 96.7% of the patients. A positive correlation was found between PSA levels and SUVmax (Spearman's r: 0.303, p<0.001). PET-PSMA detected nodal involvement in 25/89 patients (28.08%). The sensitivity, specificity, and diagnostic accuracy of PET-PSMA for detecting nodal involvement were 75%, 82.2%, and 80.9%, respectively. Patients with PSA levels>20 ng/ml, Gleason score ≥7b, ISUP grade>2, and extracapsular extension showed significantly higher SUVmax values. No differences were observed in SUVmax between risk groups or in other histopathological variables.</div></div><div><h3>Conclusions</h3><div>PET-PSMA is an effective tool for the initial staging of intermediate- and high-risk PCa. SUVmax values were significantly higher in patients with unfavorable clinical features.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500076"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Falsa imagen de recidiva ganglionar en la PET/TC con [68Ga]Ga-PSMA-11. Importancia del protocolo de adquisición PET/TC中[68Ga]Ga-PSMA-11神经节复发的假图像。采购协议的重要性

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-03-01 DOI: 10.1016/j.remn.2024.500077

C. Castillo-Arias , D. Vas , E. García , K. Quintero , M. Tormo , P. Paredes

引用次数: 0

Hallazgos de la 18F-FDG y 11C-PIB PET/TC en estatus epiléptico en el contexto de paciente con deterioro cognitivo leve 18F-FDG和11C-PIB PET/TC在轻度认知障碍患者癫痫状态中的发现

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-03-01 DOI: 10.1016/j.remn.2024.500079

M. Pombo-López, A. Bota-Bota, I. Martínez-Rodríguez, F. Gómez-de la Fuente, J. Jiménez-Bonilla, R. Quirce

引用次数: 0

Valoración de los nódulos pulmonares mediante [18F]-FDG PET/TC en inspiración profunda mantenida 使用[18F] FDG PET/TC进行持续深呼吸评估肺结节

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-03-01 DOI: 10.1016/j.remn.2024.500074

M.S. Casallas Cepeda, S. Salcedo Cortes, I. Gómez Fernández, J. Orcajo Rincón, L. Reguera Berenguer, E.J. Ardila Manjarrez, J.J. Ardila Mantilla, V. Castillo Morales, J. Guzman Cruz, D. Zamudio Rodriguez, A. Marí Hualde, J.E. Montalvá Pastor, S. Álvarez Lara, J.C. Alonso Farto

Introduction

The characterization of pulmonary nodules (PN) is a primary indication for [¹⁸F]-FDG PET/CT. However, respiratory movements hinder this characterization, especially for PN located in the lower lobes. Various methods have been developed to improve image resolution.

Objective

Our objective was to compare the diagnostic efficacy of [¹⁸F]-FDG PET/CT in deep inspiration breath-hold (DIBH) versus free-breathing corrected by software, in the evaluation of PN.

Methods

We prospectively analyzed 51 patients to assess PN using [¹⁸F]-FDG PET/CT in DIBH and free-breathing corrected by software. A total of 84 nodules with an average size of 10 mm were analyzed, with pathological anatomy or medical treatment decisions by a multidisciplinary tumor board used as reference.

Results

A total of 84 PN were evaluated, comparing those in DIBH versus free-breathing, finding statistically significant differences in SUVmax values (P<.05) (mean SUVmax 3.7 in free-breathing vs. 5.33 in DIBH). When analyzed by location in lobes, we did not find statistically significant differences, though there was a trend towards higher SUVmax values in the lower lobes. [18F]-FDG PET/CT in DIBH showed high sensitivity (95%) and negative predictive value (NPV) (92%), indicating it may be a promising tool for PN characterization.

Conclusions

The acquisition of [¹⁸F]-FDG PET/CT in DIBH significantly improves the sensitivity and diagnostic efficacy in the assessment of PN. Although no statistically significant differences were found based on location, there is a potential benefit for the lower lobes. These findings could support its use in clinical practice.

肺结节（PN）的特征是[18F]-FDG PET/CT的主要指征。然而，呼吸运动阻碍了这种表征，特别是对于位于下叶的PN。已经开发了各种方法来提高图像分辨率。目的比较[18F]-FDG PET/CT在深度吸气屏气（DIBH）和软件校正自由呼吸评估PN中的诊断效果。方法前瞻性分析51例DIBH患者，采用[18F]-FDG PET/CT评估PN，并采用软件校正自由呼吸。共分析84例平均大小为10mm的结节，并参考多学科肿瘤委员会的病理解剖或药物治疗决定。结果共评估84例PN，比较DIBH组与自由呼吸组，SUVmax值差异有统计学意义（P< 0.05）（自由呼吸组平均SUVmax 3.7， DIBH组平均SUVmax 5.33）。当按叶的位置进行分析时，我们没有发现统计学上的显著差异，尽管在较低的叶中有较高的SUVmax值的趋势。[18F]-FDG PET/CT在DIBH中显示出高灵敏度（95%）和阴性预测值（NPV）（92%），表明它可能是一种很有前途的PN表征工具。结论[18F]-FDG PET/CT对DIBH诊断PN的敏感性和诊断效能均有显著提高。虽然没有发现基于位置的统计学显著差异，但对下叶有潜在的益处。这些发现可以支持其在临床实践中的应用。

{"title":"Valoración de los nódulos pulmonares mediante [18F]-FDG PET/TC en inspiración profunda mantenida","authors":"M.S. Casallas Cepeda, S. Salcedo Cortes, I. Gómez Fernández, J. Orcajo Rincón, L. Reguera Berenguer, E.J. Ardila Manjarrez, J.J. Ardila Mantilla, V. Castillo Morales, J. Guzman Cruz, D. Zamudio Rodriguez, A. Marí Hualde, J.E. Montalvá Pastor, S. Álvarez Lara, J.C. Alonso Farto","doi":"10.1016/j.remn.2024.500074","DOIUrl":"10.1016/j.remn.2024.500074","url":null,"abstract":"<div><h3>Introduction</h3><div>The characterization of pulmonary nodules (PN) is a primary indication for [<sup>18</sup>F]-FDG PET/CT. However, respiratory movements hinder this characterization, especially for PN located in the lower lobes. Various methods have been developed to improve image resolution.</div></div><div><h3>Objective</h3><div>Our objective was to compare the diagnostic efficacy of [<sup>18</sup>F]-FDG PET/CT in deep inspiration breath-hold (DIBH) versus free-breathing corrected by software, in the evaluation of PN.</div></div><div><h3>Methods</h3><div>We prospectively analyzed 51 patients to assess PN using [<sup>18</sup>F]-FDG PET/CT in DIBH and free-breathing corrected by software. A total of 84 nodules with an average size of 10mm were analyzed, with pathological anatomy or medical treatment decisions by a multidisciplinary tumor board used as reference.</div></div><div><h3>Results</h3><div>A total of 84 PN were evaluated, comparing those in DIBH versus free-breathing, finding statistically significant differences in SUVmax values (<em>P</em><.05) (mean SUVmax 3.7 in free-breathing vs. 5.33 in DIBH). When analyzed by location in lobes, we did not find statistically significant differences, though there was a trend towards higher SUVmax values in the lower lobes. [18F]-FDG PET/CT in DIBH showed high sensitivity (95%) and negative predictive value (NPV) (92%), indicating it may be a promising tool for PN characterization.</div></div><div><h3>Conclusions</h3><div>The acquisition of [<sup>18</sup>F]-FDG PET/CT in DIBH significantly improves the sensitivity and diagnostic efficacy in the assessment of PN. Although no statistically significant differences were found based on location, there is a potential benefit for the lower lobes. These findings could support its use in clinical practice.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500074"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enfermedad por micropartículas en prótesis de cadera, a propósito de un caso 髋关节假体中的微粒病，以病例为例

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-03-01 DOI: 10.1016/j.remn.2024.500078

J.L. Díaz Moreno, I.E. Sánchez-Rodríguez, B. Hervás-Sanz, P. Notta-González, C. Martínez-Ramos, L. Gràcia-Sánchez

引用次数: 0

Papel y aplicaciones de la [18F]FDG PET/TC en la evaluación de la infección e inflamación osteoarticular. Parte II [18F]FDG PET/TC在骨关节感染和炎症评估中的作用和应用。第二部分

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-03-01 DOI: 10.1016/j.remn.2024.500102

E. Noriega-Álvarez , B. Rodríguez Alfonso , J.J. Rosales Castillo , A. Moreno Ballesteros , E. López Rodríguez , S. Sanz Viedma , M.P. Orduña Diez , L. Domínguez Gadea

[¹⁸F]FDG PET/TC is an emerging tool in the evaluation of inflammatory arthropathies, characterised by their insidious course and clinical overlap. It allows detection of subclinical inflammation, assessment of systemic involvement and quantification of metabolic parameters useful in early diagnosis and therapeutic monitoring. In rheumatoid arthritis, it correlates with clinical indices (Disease Activity Score), serological markers (CRP, anti-citrullinated protein antibodies) and ultrasound findings, and facilitates the identification of complications such as cardiovascular and pulmonary involvement. In spondyloarthritis, its ability to identify enthesitis and peripheral synovitis is promising, although less studied. In addition, [¹⁸F]FDG PET/TC evaluates the response to biological treatments, helping to optimise therapeutic decisions. However, its implementation faces challenges such as lack of standardised indications, incidental findings and technical artefacts. Although not routinely recommended, its usefulness in specific settings underlines the need for further studies to consolidate its role in the management of these diseases. In this manuscript, we present a brief review providing general and practical information about the role of [¹⁸F]FDG PET/TC in inflammatory osteoarticular pathology, while “Role and applications of [¹⁸F]FDG PET/CT in the assessment of osteoarticular infection and inflammation - Part I” has addressed its role in infectious osteoarticular disease.

[18F]FDG PET/TC是评估炎性关节病的新兴工具，其特点是病程隐匿且临床重叠。它可以检测亚临床炎症，评估全身受累和量化代谢参数，有助于早期诊断和治疗监测。在类风湿关节炎中，它与临床指标（疾病活动评分）、血清学标志物（CRP、抗瓜氨酸化蛋白抗体）和超声检查结果相关，有助于识别心血管和肺部受累等并发症。在脊柱性关节炎中，虽然研究较少，但其识别骨髓炎和周围滑膜炎的能力是有希望的。此外，[18F]FDG PET/TC评估对生物治疗的反应，有助于优化治疗决策。然而，它的实施面临着诸如缺乏标准化适应症、偶然发现和技术人工制品等挑战。虽然没有常规推荐，但它在特定情况下的有用性强调了需要进一步研究以巩固其在这些疾病管理中的作用。在这篇文章中，我们简要回顾了[18F]FDG PET/TC在炎症性骨关节病理中的作用，提供了一般和实用的信息，而“[18F]FDG PET/CT在骨关节感染和炎症评估中的作用和应用-第一部分”阐述了它在感染性骨关节疾病中的作用。

{"title":"Papel y aplicaciones de la [18F]FDG PET/TC en la evaluación de la infección e inflamación osteoarticular. Parte II","authors":"E. Noriega-Álvarez , B. Rodríguez Alfonso , J.J. Rosales Castillo , A. Moreno Ballesteros , E. López Rodríguez , S. Sanz Viedma , M.P. Orduña Diez , L. Domínguez Gadea","doi":"10.1016/j.remn.2024.500102","DOIUrl":"10.1016/j.remn.2024.500102","url":null,"abstract":"<div><div>[<sup>18</sup>F]FDG PET/TC is an emerging tool in the evaluation of inflammatory arthropathies, characterised by their insidious course and clinical overlap. It allows detection of subclinical inflammation, assessment of systemic involvement and quantification of metabolic parameters useful in early diagnosis and therapeutic monitoring. In rheumatoid arthritis, it correlates with clinical indices (<em>Disease Activity Score</em>), serological markers (CRP, anti-citrullinated protein antibodies) and ultrasound findings, and facilitates the identification of complications such as cardiovascular and pulmonary involvement. In spondyloarthritis, its ability to identify enthesitis and peripheral synovitis is promising, although less studied. In addition, [<sup>18</sup>F]FDG PET/TC evaluates the response to biological treatments, helping to optimise therapeutic decisions. However, its implementation faces challenges such as lack of standardised indications, incidental findings and technical artefacts. Although not routinely recommended, its usefulness in specific settings underlines the need for further studies to consolidate its role in the management of these diseases. In this manuscript, we present a brief review providing general and practical information about the role of [<sup>18</sup>F]FDG PET/TC in inflammatory osteoarticular pathology, while “Role and applications of [<sup>18</sup>F]FDG PET/CT in the assessment of osteoarticular infection and inflammation - Part I” has addressed its role in infectious osteoarticular disease.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500102"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utilidad de la PET/TC con [18F]F-fluorocolina en la valoración de respuesta a la terapia antiandrogénica en pacientes con cáncer de próstata 含[18F]氟胆碱的PET/TC在评估前列腺癌患者抗雄激素治疗反应中的作用

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-03-01 DOI: 10.1016/j.remn.2024.500083

K. Quintero , E. Vila , L. Ferrer-Mileo , D. Vas , Maria J. Ribal , M. Garcia-Herreros , N. Navarro , M. Tormo-Ratera , C. Aversa , A. Vilaseca , A. Farré-Melero , D. Fuster , P. Paredes , grupo de Medicina Nuclear Clínic Barcelona (MNCB)

Objective

To evaluate the correlation between response assessment measured by PET/CT with [¹⁸F] F-fluorocholine (Choline PET/CT) and serum levels of PSA in patients with prostate cancer under antiandrogenic treatment.

Methodology

A retrospective study included patients with CRPC and CSPC treated with enzalutamide, abiraterone, or apalutamide between June 2018 and July 2021, who underwent baseline and a follow-up Choline PET/CT. The difference in maximum SUVmax (ΔSUV) between both studies and the PSA value before and at follow-up were recorded. The response to treatment was compared by PSA vs. PET, assessing their association, agreement, and correlation.

Results

Thirty patients were included (median age 74 years, range 68-78), 12 with CSPC and 18 with CRPC; 22 had nodal disease, and 15 had active bone disease. The average time between pre-treatment and follow-up PET/CT was 11 months (range 3.5-23).

Patients with extra-nodal metastatic disease at the beginning of treatment showed a higher correlation between PSA and ΔSUV (OR 4.375). In patients with bone disease at the start of treatment, 80% were classified as non-responders on PET response assessment, while only 40% were non-responders by PSA.

The correlation between PET and PSA was mild (Kendall's tau_b 0.26), and the classification into Responders/Non-responders had only slight agreement (Cohen's kappa 0.30).

Conclusion

Choline PET/CT shows low concordance with the PSA values obtained during the follow-up of response to anti-androgen therapy, especially in patients with bone involvement.

目的探讨抗雄激素治疗前列腺癌患者用[18F] f -氟胆碱PET/CT （Choline PET/CT）测定的疗效评价与血清PSA水平的相关性。回顾性研究纳入了2018年6月至2021年7月期间接受恩杂鲁胺、阿比特龙或阿帕鲁胺治疗的CRPC和CSPC患者，这些患者接受了基线和随访的胆碱PET/CT检查。记录两项研究的最大SUVmax （ΔSUV）与随访前和随访时PSA值的差异。通过PSA和PET比较对治疗的反应，评估它们的相关性、一致性和相关性。结果30例患者（中位年龄74岁，68 ~ 78岁），其中CSPC 12例，CRPC 18例；22例为结节性疾病，15例为活动性骨病。从治疗前到随访PET/CT平均时间为11个月（范围3.5-23）。治疗开始时淋巴结外转移性疾病患者的PSA与ΔSUV的相关性更高（OR 4.375）。在治疗开始时患有骨病的患者中，80%的人在PET反应评估中被归类为无反应，而只有40%的人在PSA中被归类为无反应。PET与PSA之间的相关性较弱（Kendall的tau_b为0.26），而应答者/无应答者的分类只有轻微的一致性（Cohen的kappa为0.30）。结论胆碱PET/CT与抗雄激素治疗应答随访时PSA值一致性较低，尤其是累及骨的患者。

{"title":"Utilidad de la PET/TC con [18F]F-fluorocolina en la valoración de respuesta a la terapia antiandrogénica en pacientes con cáncer de próstata","authors":"K. Quintero , E. Vila , L. Ferrer-Mileo , D. Vas , Maria J. Ribal , M. Garcia-Herreros , N. Navarro , M. Tormo-Ratera , C. Aversa , A. Vilaseca , A. Farré-Melero , D. Fuster , P. Paredes , grupo de Medicina Nuclear Clínic Barcelona (MNCB)","doi":"10.1016/j.remn.2024.500083","DOIUrl":"10.1016/j.remn.2024.500083","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the correlation between response assessment measured by PET/CT with [<sup>18</sup>F] F-fluorocholine (Choline PET/CT) and serum levels of PSA in patients with prostate cancer under antiandrogenic treatment.</div></div><div><h3>Methodology</h3><div>A retrospective study included patients with CRPC and CSPC treated with enzalutamide, abiraterone, or apalutamide between June 2018 and July 2021, who underwent baseline and a follow-up Choline PET/CT. The difference in maximum SUVmax (ΔSUV) between both studies and the PSA value before and at follow-up were recorded. The response to treatment was compared by PSA vs. PET, assessing their association, agreement, and correlation.</div></div><div><h3>Results</h3><div>Thirty patients were included (median age 74 years, range 68-78), 12 with CSPC and 18 with CRPC; 22 had nodal disease, and 15 had active bone disease. The average time between pre-treatment and follow-up PET/CT was 11 months (range 3.5-23).</div><div>Patients with extra-nodal metastatic disease at the beginning of treatment showed a higher correlation between PSA and ΔSUV (OR 4.375). In patients with bone disease at the start of treatment, 80% were classified as non-responders on PET response assessment, while only 40% were non-responders by PSA.</div><div>The correlation between PET and PSA was mild <em>(Kendall's tau_b</em> 0.26), and the classification into Responders/Non-responders had only slight agreement (<em>Cohen's kappa</em> 0.30).</div></div><div><h3>Conclusion</h3><div>Choline PET/CT shows low concordance with the PSA values obtained during the follow-up of response to anti-androgen therapy, especially in patients with bone involvement.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500083"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Valor clínico de un PET/TC con [18F]F-PSMA negativo en pacientes diagnosticados de cáncer de próstata tratados con prostatectomía con elevación del PSA, inferior a 1 ng/ml, en los resultados de la radioterapia de rescate 在接受前列腺切除术治疗、PSA升高小于1纳克/毫升的前列腺癌患者中，具有[18F]F-PSMA阴性的PET/ CT临床值

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-03-01 DOI: 10.1016/j.remn.2024.500071

M. Cózar Santiago , J. García Garzón , A. Esteban Hurtado , J. Pastor Peiro , J. Ferrer Rebolleda

Objective

To assess the clinical value of [¹⁸F]F-PSMA negative PET/CT, in patients diagnosed with prostate cancer treated with prostatectomy with elevated PSA less than 1 ng/mL, on the outcome of salvage radiotherapy.

Method

We prospectively included 98 patients diagnosed with prostate cancer treated with prostatectomy with biochemical recurrence [mean PSA 0.51 ng/mL (range 0.17-1,0 ng/mL)] who were referred for an [¹⁸F]F-PSMA-PET/CT study.

The [¹⁸F]F-PSMA-PET/CT scan was negative in 53/98 patients (54.09%). Differences were analysed between those patients who were or were not candidates for pelvic salvage radiotherapy (PSRT) decided upon multidisciplinary committee and patient consent, with a minimum follow-up time for 1 year. Response to treatment was defined as a 50% reduction in PSA levels. Recurrence was ascertained upon clinical, analytical and imaging follow-up outcomes.

Results

54.7% (29/53) of the patients with a negative [¹⁸F]F-PSMA-PET/CT underwent PSRT. Of these, 93.1% (27/29) patients demonstrated response to treatment (PSMA false negatives). The remaining two patients showed fluctuating PSA levels without detecting disease on the [¹⁸F]F-PSMA-PET/CT follow-up study.

45.3% (24/53) of patients with negative [¹⁸F]F-PSMA-PET/CT did not undergo PSRT. Of these, progressive PSA elevation was observed in 62.5% (15/24) (PSMA false negatives), localising recurrence on the [¹⁸F]F-PSMA-PET/CT follow-up study in 4 patients. The remaining 9 patients (37.5%) showed fluctuating PSA levels without detecting disease on the [¹⁸F]F-PSMA-PET/CT follow-up study.

Our series confirmed 42 (42.85%) [¹⁸F]F-PSMA-PET/CT false negatives cases.

Conclusion

Patients diagnosed with prostate cancer with post-prostatectomy biochemical recurrence and a negative [¹⁸F]F-PSMA-PET/CT study are likely to benefit from pelvic salvage radiotherapy, with response seen in 93.1% of our cases.

目的探讨[18F]F-PSMA阴性PET/CT对前列腺癌行前列腺切除术且PSA升高小于1 ng/mL患者补救性放疗预后的临床价值。方法前瞻性纳入98例经前列腺切除术诊断为前列腺癌并生化复发的患者[平均PSA 0.51 ng/mL（范围0.17-1,0 ng/mL）]，转介进行[18F]F-PSMA-PET/CT研究。[18F]F-PSMA-PET/CT扫描阴性53/98例（54.09%）。经多学科委员会和患者同意决定是否接受盆腔保留放疗（PSRT）的患者之间进行差异分析，随访时间至少为1年。对治疗的反应被定义为PSA水平降低50%。结果54.7%（29/53）的F-PSMA-PET/CT阴性患者接受了PSRT治疗。其中，93.1%（27/29）患者表现出对治疗的反应（PSMA假阴性）。其余2例患者在[18F]F-PSMA-PET/CT随访研究中显示PSA水平波动，但未发现疾病，45.3%（24/53）的[18F]F-PSMA-PET/CT阴性患者未进行PSRT。其中，62.5%（15/24）的患者出现进行性PSA升高（PSMA假阴性），在[18F]F-PSMA-PET/CT随访研究中，4例患者出现局部复发。其余9例（37.5%）患者在[18F]F-PSMA-PET/CT随访研究中显示PSA水平波动，但未发现疾病。本组共确诊42例（42.85%）[18F]F-PSMA-PET/CT假阴性。结论诊断为前列腺癌的前列腺切除术后生化复发且F-PSMA-PET/CT阴性的患者可能受益于盆腔补救性放疗，93.1%的病例有反应。

{"title":"Valor clínico de un PET/TC con [18F]F-PSMA negativo en pacientes diagnosticados de cáncer de próstata tratados con prostatectomía con elevación del PSA, inferior a 1 ng/ml, en los resultados de la radioterapia de rescate","authors":"M. Cózar Santiago , J. García Garzón , A. Esteban Hurtado , J. Pastor Peiro , J. Ferrer Rebolleda","doi":"10.1016/j.remn.2024.500071","DOIUrl":"10.1016/j.remn.2024.500071","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the clinical value of [<sup>18</sup>F]F-PSMA negative PET/CT, in patients diagnosed with prostate cancer treated with prostatectomy with elevated PSA less than 1ng/mL, on the outcome of salvage radiotherapy.</div></div><div><h3>Method</h3><div>We prospectively included 98 patients diagnosed with prostate cancer treated with prostatectomy with biochemical recurrence [mean PSA 0.51ng/mL (range 0.17-1,0ng/mL)] who were referred for an [<sup>18</sup>F]F-PSMA-PET/CT study.</div><div>The [<sup>18</sup>F]F-PSMA-PET/CT scan was negative in 53/98 patients (54.09%). Differences were analysed between those patients who were or were not candidates for pelvic salvage radiotherapy (PSRT) decided upon multidisciplinary committee and patient consent, with a minimum follow-up time for 1year. Response to treatment was defined as a 50% reduction in PSA levels. Recurrence was ascertained upon clinical, analytical and imaging follow-up outcomes.</div></div><div><h3>Results</h3><div>54.7% (29/53) of the patients with a negative [<sup>18</sup>F]F-PSMA-PET/CT underwent PSRT. Of these, 93.1% (27/29) patients demonstrated response to treatment (PSMA false negatives). The remaining two patients showed fluctuating PSA levels without detecting disease on the [<sup>18</sup>F]F-PSMA-PET/CT follow-up study.</div><div>45.3% (24/53) of patients with negative [<sup>18</sup>F]F-PSMA-PET/CT did not undergo PSRT. Of these, progressive PSA elevation was observed in 62.5% (15/24) (PSMA false negatives), localising recurrence on the [<sup>18</sup>F]F-PSMA-PET/CT follow-up study in 4 patients. The remaining 9 patients (37.5%) showed fluctuating PSA levels without detecting disease on the [<sup>18</sup>F]F-PSMA-PET/CT follow-up study.</div><div>Our series confirmed 42 (42.85%) [<sup>18</sup>F]F-PSMA-PET/CT false negatives cases.</div></div><div><h3>Conclusion</h3><div>Patients diagnosed with prostate cancer with post-prostatectomy biochemical recurrence and a negative [<sup>18</sup>F]F-PSMA-PET/CT study are likely to benefit from pelvic salvage radiotherapy, with response seen in 93.1% of our cases.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500071"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0